APVO

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.

Wall Street analysts forecast APVO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for APVO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aptevo Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Aptevo Therapeutics Inc. EPS for the last quarter amounts to -2.23 USD, decreased -99.38 % YoY.

Aptevo Therapeutics Inc (APVO) has 37 emplpoyees as of January 07 2026.

Today APVO has the market capitalization of 7.44M USD.